Evidence map›Paper›PMID 21416055›Full record

ArticleAmerican journal of translational research2011

Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer.

Zhiyong Liao, Marja T Nevalainen

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Targeting the JAK/STAT signalling axis in cancer: chemopreventive potential of natural compounds with emerging focus on retinoids.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhiyong Liao
Marja T Nevalainen

Funding

Stat5 in Progression of Prostate CancerR01CA113580 · NCI · THOMAS JEFFERSON UNIVERSITY · PI NEVALAINEN, MARJA T · 2006 to 2015
$2.7M
NCI NIH HHS R01 CA113580
6 · The paper itself

Abstract

Signal transducer and activator of transcription 5 (Stat5) is critical for the viability and growth of human prostate cancer cells in culture and for prostate xenograft tumors in nude mice. The expression of nuclear active Stat5a/b is associated with high histological grades of clinical prostate cancers, and the presence of active Stat5a/b in prostate cancer predicts early disease recurrence. Stat5a/b and androgen receptor signaling pathways functionally synergize in prostate cancer cells, and recent work suggests that Stat5a/b may be involved in the progression of prostate cancer to metastatic disease. Here, we review the biological functions of Stat5a/b in prostate cancer and potential strategies to target the prolactin receptor (PrlR)/Jak2/Stat5 signaling pathway for therapy development for prostate cancer.

Indexed as

prolactin receptor-Jak2-Stat5a/b signaling pathwayProstate cancertherapy development

Identifiers

PMID21416055
PMCPMC3056559
OpenAlexW2247831904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.